Submissions for variant NM_000059.4(BRCA2):c.8537_8538del (p.Glu2846fs)

dbSNP: rs80359714

Total submissions: 26

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)	RCV000009915	SCV000301287	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2016-09-08	reviewed by expert panel	curation	Variant allele predicted to encode a truncated non-functional protein.
Labcorp Genetics (formerly Invitae), Labcorp	RCV000045550	SCV000073563	pathogenic	Hereditary breast ovarian cancer syndrome	2024-01-29	criteria provided, single submitter	clinical testing	This sequence change creates a premature translational stop signal (p.Glu2846Glyfs*22) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant is present in population databases (rs80359714, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with breast and/or ovarian cancer (PMID: 8673090, 21324516, 22401979). It is commonly reported in individuals of French Canadian, Yemenite Jewish, and Northern Sardinian ancestry (PMID: 9634522, 9792861, 11512557, 15382066, 17640379, 19619314, 27603373). This variant is also known as 8765delAG. ClinVar contains an entry for this variant (Variation ID: 9328). For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics	RCV000131085	SCV000186015	pathogenic	Hereditary cancer-predisposing syndrome	2024-03-26	criteria provided, single submitter	clinical testing	The c.8537_8538delAG (p.E2846Gfs*22) alteration, located in exon 20 (coding exon 19) of the BRCA2 gene, consists of a deletion of 2 nucleotides from position 8537 to 8538, causing a translational frameshift with a predicted alternate stop codon after 22 amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. This mutation has been reported in multiple individuals and families with hereditary breast and ovarian cancer (HBOC) syndrome (Foretova, 2004; Palomba, 2005; Machackova, 2008; Zhang, 2011; Abd-Rabbo, 2012; Belanger, 2015; El Ghorayeb, 2016; Carter, 2018; Bernstein-Molho, 2018; Felix, 2018; Lowery, 2018; Breast Cancer Association, 2021) and has also been reported in a family with a history of male breast and prostate cancer (Phelan, 1996). This mutation has also been reported in patients with pancreatic and gastric cancers (Halpern, 2020;Lerner-Ellis, 2021). This alteration is known to be one of the more commonly occurring BRCA2 mutations in several different regions in Europe and North America (Tonin, 1998; Manning, 2001; Palomba, 2007; Janaviius, 2010). Of note, this alteration is also designated as 8535delAG, 8765delAG, c.8764_8765delAG and c.8537_8538del2 in published literature. Based on the available evidence, this alteration is classified as pathogenic.
GeneDx	RCV000160308	SCV000210795	pathogenic	not provided	2020-02-17	criteria provided, single submitter	clinical testing	Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (Lek 2016); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Also known as 8765delAG and 8765_8766delAG; This variant is associated with the following publications: (PMID: 23929434, 8673090, 16168118, 18489799, 21947752, 23302520, 23621881, 10422801, 15024741, 20694749, 26295337, 30014164, 28918466, 29086229, 29506128, 23199084, 25884701, 19656164, 26656232, 17640379, 25452441, 22798144, 21348412, 27836010, 27603373, 27160020, 25085752, 19619314, 15382066, 11512557, 9792861, 9634522, 21324516, 17591843, 16047344, 29560538, 22401979, 30720243, 30322717, 29625052)
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario	RCV000735482	SCV000219410	pathogenic	Breast and/or ovarian cancer	2023-06-16	criteria provided, single submitter	clinical testing
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000045550	SCV000271336	pathogenic	Hereditary breast ovarian cancer syndrome	2016-02-08	criteria provided, single submitter	clinical testing	The p.Glu2846fs variant in BRCA2 is a well-established pathogenic founder varian t for several populations, including French Canadians, Jewish-Yemenites, and Nor thern Sardinian (Tonin 1998, Lerer 1998, Ferla 2007). This variant has been ide ntified in 1/66688 European chromosomes by the Exome Aggregation Consortium (ExA C, http://exac.broadinstitute.org; dbSNP rs80359716). This frequency is low enou gh to be consistent with the frequency of hereditary breast and ovarian cancer ( HBOC) in the general population. This variant is predicted to cause a frameshift , which alters the protein?s amino acid sequence beginning at position 2846 and leads to a premature termination codon 22 amino acids downstream. This alteratio n is then predicted to lead to a truncated or absent protein. Heterozygous loss of BRCA2 function is an established disease mechanism in HBOC. In summary, this variant meets our criteria to be classified as pathogenic for HBOC in an autosom al dominant manner.
Quest Diagnostics Nichols Institute San Juan Capistrano	RCV000160308	SCV000296650	pathogenic	not provided	2021-01-05	criteria provided, single submitter	clinical testing	This frameshift variant causes the premature termination of BRCA2 protein synthesis. In addition, it has been reported in individuals affected with breast cancer, ovarian cancer, and pancreatic cancer in the published literature (PMID: 30322717 (2018), 29625052 (2018), 29506128 (2018), 29086229 (2018), 21324516 (2011)). Based on the available information, this variant is classified as pathogenic.
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge	RCV000009915	SCV000327919	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2015-10-02	criteria provided, single submitter	clinical testing
Counsyl	RCV000009915	SCV000489211	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2016-09-16	criteria provided, single submitter	clinical testing
Department of Pathology and Molecular Medicine, Queen's University	RCV000045550	SCV000588121	pathogenic	Hereditary breast ovarian cancer syndrome	2017-04-20	criteria provided, single submitter	clinical testing
Color Diagnostics, LLC DBA Color Health	RCV000131085	SCV000683979	pathogenic	Hereditary cancer-predisposing syndrome	2023-05-31	criteria provided, single submitter	clinical testing	This variant deletes 2 nucleotides in exon 20 of the BRCA2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. To our knowledge, functional studies have not been reported for this variant. This variant has been reported as a recurring pathogenic variant in French Canadian, Sardinian, and Yemenite Jewish populations (PMID: 9792861, 17640379, 23621881, 29086229). This variant has been identified in 3/251142 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000045550	SCV000916958	pathogenic	Hereditary breast ovarian cancer syndrome	2022-06-03	criteria provided, single submitter	clinical testing	Variant summary: BRCA2 c.8537_8538delAG (p.Glu2846GlyfsX22) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 1.2e-05 in 251142 control chromosomes. c.8537_8538delAG has been reported in the literature in many individuals and families affected with Hereditary Breast And Ovarian Cancer Syndrome (example Phelan_1996, Machackova_2008, Ghadirian_2014) including 76 patients from the BIC database. It is commonly reported as a pathogenic variant in French Canadian, Yemenite Jewish, and Northern Sardinian populations (example Lerer_1998, Manning_2001, Palomba_ 2007). These data indicate that the variant is very likely to be associated with disease. Multiple clinical diagnostic laboratories and reputable databases have classified this variant as pathogenic in ClinVar. Based on the evidence outlined above, the variant was classified as pathogenic.
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden	RCV000160308	SCV002010306	pathogenic	not provided	2021-11-03	criteria provided, single submitter	clinical testing
AiLife Diagnostics, AiLife Diagnostics	RCV000160308	SCV002503465	pathogenic	not provided	2021-07-23	criteria provided, single submitter	clinical testing
Revvity Omics, Revvity	RCV000160308	SCV003813739	pathogenic	not provided	2022-11-29	criteria provided, single submitter	clinical testing
Baylor Genetics	RCV003460447	SCV004213708	pathogenic	Familial cancer of breast	2024-03-07	criteria provided, single submitter	clinical testing
All of Us Research Program, National Institutes of Health	RCV000009915	SCV004846036	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2023-10-02	criteria provided, single submitter	clinical testing	This variant deletes 2 nucleotides in exon 20 of the BRCA2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. To our knowledge, functional studies have not been reported for this variant. This variant has been reported as a recurring pathogenic variant in French Canadian, Sardinian, and Yemenite Jewish populations (PMID: 9792861, 17640379, 23621881, 29086229). This variant has been identified in 3/251142 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Mayo Clinic Laboratories, Mayo Clinic	RCV000160308	SCV005414167	pathogenic	not provided	2024-08-30	criteria provided, single submitter	clinical testing	PM5_strong, PVS1
OMIM	RCV000009915	SCV000030136	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	1998-07-01	no assertion criteria provided	literature only
Sharing Clinical Reports Project (SCRP)	RCV000009915	SCV000054357	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2013-04-22	no assertion criteria provided	clinical testing
Breast Cancer Information Core (BIC) (BRCA2)	RCV000009915	SCV000147396	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2002-05-29	no assertion criteria provided	clinical testing
Pathway Genomics	RCV000009915	SCV000189901	pathogenic	Breast-ovarian cancer, familial, susceptibility to, 2	2014-07-24	no assertion criteria provided	clinical testing
Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto	RCV000045550	SCV000587959	pathogenic	Hereditary breast ovarian cancer syndrome	2014-01-31	no assertion criteria provided	research
Department of Pathology and Laboratory Medicine, Sinai Health System	RCV001353461	SCV000592208	pathogenic	Malignant tumor of breast		no assertion criteria provided	clinical testing	The BRCA2 p.Glu2846GlyfsX22 variant was identified in 21 of 4958 proband chromosomes (frequency: 0.004) from individuals or families with breast and ovarian cancer (Phelan 1996, Zhang 2011, Machackova 2008, Pruss 2014, Seong M-W 2009, Tung 2016). The variant was also identified in the following databases: dbSNP (ID: rs80359714) as “With Pathogenic allele”, Clinvitae database (classified as pathogenic by ClinVar and Invitae), ARUP Laboratories BRCA Mutations Database (classification), the ClinVar database (classified as pathogenic by Invitae, Ambry genetics, GeneDx, LMMPHPM, QDNISJC, COGR, Pathway Genomics, BIC,OMIM, SCRP), COGR database (classified as pathogenic by a clinical laboratories MESHWCRI, LMM, CHEO, QUEENSU, NYG), the BIC database (76X with clinical importance), and UMD (16X with a causal classification). The variant was also identified in Exome Aggregation Consortium database (August 8, 2016) in the European population in 1 of 121324 chromosomes (freq. 0.000008). The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. The c.8537_8538del variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 2846 and leads to a premature stop codon 22 codons downstream. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the BRCA2 gene are an established mechanism of disease in hereditary breast and ovarian cancer and is the type of variant expected to cause the disorder. In summary, based on the above information, this variant meets our laboratory’s criteria to be classified as pathogenic.
Foulkes Cancer Genetics LDI, Lady Davis Institute for Medical Research	RCV000735482	SCV000863619	pathogenic	Breast and/or ovarian cancer	2016-05-11	no assertion criteria provided	clinical testing
CZECANCA consortium	RCV000735482	SCV001451887	pathogenic	Breast and/or ovarian cancer	2019-06-11	no assertion criteria provided	clinical testing